Expand all sections

Mometasone furoate sinus drug depot

Extended indication Chronic rhinosinusitis (CRS) patients who have had a prior functional endoscopic sinus surgery.
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Mometasone furoate sinus drug depot
Domain Lung diseases
Reason of inclusion New medicine (specialité)
Main indication Lung diseases other
Extended indication Chronic rhinosinusitis (CRS) patients who have had a prior functional endoscopic sinus surgery.
Manufacturer Intas
Route of administration Nasal
Budgetting framework Intermural (MSZ)
Additional remarks Werkingsmechaninsme: Glucocorticoid receptor agonist

Registration

Registration route Centralised (EMA)
ATMP No
Submission date September 2024
Expected Registration October 2025
Registration phase Clinical trials
Additional remarks NCT05219968

Therapeutic value

Therapeutic value No estimate possible yet
Dosage per administration 7500 µg

Expected patient volume per year

References https://richtlijnen.nhg.org/standaarden/acute-rhinosinusitis#:~:text=De%20incidentie%20van%20rhinosinusitis%20(zowel,vaker%20voor%20dan%20bij%20mannen.
Additional remarks De incidentie van rhinosinusitis (zowel acuut als chronisch) in de huisartsenpraktijk wordt geschat op 30 per 1.000 patiënten per jaar.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.